A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population

NCT02626754 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER_GOV

Sponsor class

Stopped In most sites had difficult to recruitting subjects.

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Sunitinib malate

Sponsor

vghtpe user